# Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients

Source: https://onco.cc/trials/nct07809893/  
OnCo record `nct07809893` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by Sun Yat-sen University, now recruiting.

## Summary

Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients is a phase 2, interventional study registered as NCT07809893 by Sun Yat-sen University, with a registry enrolment figure of 45 participants, started 2026-08-10 and due to reach its primary completion in 2027-12-31. Interventions recorded: Ivonescimab +mFOLFOXIRI +celecoxib. Conditions listed: Colorectal Cancer. Primary outcome: Objective response rate (ORR). Colorectal eligibility wording from the registry: "Colorectal adenocarcinoma with definite histological evidence, with evidence of distant metastasis;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07809893
- Phase: 2
- Setting: Ivosidenib Plus mFOLFOXIRI and Celecoxib as a Treatment for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients: a Phase II Study
- Sponsor: Sun Yat-sen University
- Enrolled: 45

## Sources

- ClinicalTrials.gov NCT07809893: https://clinicaltrials.gov/study/NCT07809893

## Connected records

- cancers: [BRAF V600E-mutant colorectal cancer](https://onco.cc/cancers/braf-v600e-colorectal/), [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07809893.json